Streetbeat News

Equity Actions

ADTX

Aditxt, Inc. (ADTX) announced a private placement of 1,237,114 shares at $4.85 per share, raising $6 million. This move has helped the company regain compliance with Nasdaq's Stockholders' equity requirement, but the stock is trading lower following the announcement.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:24 pm

ADTX

Aditxt, Inc. (ADTX) announced a private placement of 1,237,114 shares at $4.85/share, with accompanying warrants exercisable at $4.60/share. The placement is expected to close on January 3, 2024, with gross proceeds of $6 million. The funds are intended for working capital and general corporate purposes. Certain existing warrants will be amended to have a reduced exercise price of $4.60/share.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:15 pm

ALID

BBRRF

Blueberries Medical Corp. (OTC:BBRRF) announced a non-brokered private placement of 180,716,00 common shares at $0.0083 per share, raising approximately $1.99 million. The proceeds will repay debt and support general corporate purposes. The offering was led by Terraflos Inc., with plans to expand into Argentina, Mexico, and Brazil. Blueberries also has a joint venture with Allied Corp. (OTCQB:ALID) for the production of cannabis derivatives. Post-announcement, BBRRF shares rose 12.7451% to $0.0138.

Portfolio Pulse from Jelena Martinovic

January 02, 2024 | 4:10 pm

AUR

Aurora Innovation Inc (NASDAQ:AUR) shares dropped 11.6% to $3.86 after announcing plans to issue securities up to $850 million. The company intends to use the funds for operational needs and potential investments in new technologies or businesses, although no specific agreements are in place. The plans are subject to change based on business conditions, and in the interim, funds may be placed in secure, interest-bearing assets.

Portfolio Pulse from Henry Khederian

January 02, 2024 | 4:03 pm

ROIV

Five financial analysts have provided varied opinions on Roivant Sciences (NASDAQ:ROIV) over the past three months, with recent ratings showing 3 bullish, 1 somewhat bullish, and 1 indifferent. The average 12-month price target is $14.8, with a high of $17.00 and a low of $12.00, slightly up from the previous $14.67 average. Analysts from B of A Securities, Deutsche Bank, Guggenheim, and JP Morgan have adjusted their ratings and price targets, reflecting their latest views on the company's performance. Roivant Sciences, a biopharmaceutical company, has shown a significant revenue growth rate of 196.03% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -820.27%, ROE of -32.74%, and ROA of -14.48%.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:01 pm

TGT

Target Corporation (NYSE:TGT) has seen a surge in options activity, with a notable division in sentiment among investors. Benzinga's options scanner detected 17 unusual options activities, with 58% bullish and 41% bearish. The options suggest a targeted price range of $120 to $175 for Target over the last 3 months. The most significant options trades include bearish puts and bullish calls with various expiration dates and strike prices. Target is the sixth-largest retailer in the U.S., with over 1,900 stores and annual sales over $100 billion. The stock price is currently up 0.73% at $143.46, with potential overbought signals from RSI indicators. Target's next earnings report is expected in 56 days.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

AUR

Aurora Innovation's stock is trading lower following the company's filing for an $850 million mixed securities shelf offering, which could dilute existing shareholders' equity.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:00 pm

CFLT

Confluent Inc (NASDAQ:CFLT) has received mixed analyst ratings over the past three months, with 17 analysts offering diverse perspectives. The average 12-month price target is $26.71, a significant decrease from the previous $38.56. Analysts have adjusted their ratings and price targets, with some raising and others lowering their expectations. Confluent's financials show a revenue growth rate of 31.93% as of September 30, 2023, but it struggles with a net margin of -46.29%, an ROE of -11.95%, an ROA of -3.95%, and a high debt-to-equity ratio of 1.41.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

AVY

Avery Dennison (NYSE:AVY) received mixed analyst ratings over the past three months, with 3 bullish and 1 underperform rating. The 12-month price target average for AVY is $209.00, slightly down from the previous $210.00. Analysts from B of A Securities, Truist Securities, and Citigroup have provided recent evaluations, with price target adjustments reflecting their latest views on the company's performance. Avery Dennison's financials show a revenue decline of -9.44% over the past 3 months, but strong profitability with a net margin of 6.59% and ROE of 6.78%. The company's international operations contribute significantly to its sales, and it maintains a balanced debt approach with a debt-to-equity ratio of 1.61.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

ABNB

The analysis compares Airbnb (ABNB) with competitors in the Hotels, Restaurants & Leisure industry, focusing on financial metrics like P/E, P/B, P/S, ROE, EBITDA, gross profit, and revenue growth. Airbnb shows potential undervaluation with a lower P/E and P/B than the industry average, but a higher P/S ratio suggests overvaluation in sales. The company's high ROE, EBITDA, and gross profit indicate strong profitability, despite lower revenue growth compared to the industry. Airbnb's lower debt-to-equity ratio suggests a stronger financial position with less reliance on debt.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm